Clinical Trial Update: Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb [Phase 2]

View source ↗

Summary

Phase 2 translational study investigating molecular predictors of resistance to first-line pazopanib in metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED